NASDAQ:ALKS Alkermes (ALKS) Stock Price, News & Analysis $27.11 -0.68 (-2.45%) (As of 10/8/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Alkermes Stock (NASDAQ:ALKS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Alkermes alerts:Sign Up Key Stats Today's Range$27.11▼$27.9250-Day Range$25.94▼$29.0052-Week Range$22.01▼$32.88Volume1.46 million shsAverage Volume1.83 million shsMarket Capitalization$4.59 billionP/E Ratio10.72Dividend YieldN/APrice Target$36.70Consensus RatingModerate Buy Company OverviewAlkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.Read More… Ex WH Advisor Who Predicted Biden Leaving Race Makes Startling New Prediction (Ad)Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… Alkermes Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks88th Percentile Overall ScoreALKS MarketRank™: Alkermes scored higher than 88% of companies evaluated by MarketBeat, and ranked 144th out of 994 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingAlkermes has received a consensus rating of Moderate Buy. The company's average rating score is 2.55, and is based on 7 buy ratings, 3 hold ratings, and 1 sell rating.Amount of Analyst CoverageAlkermes has only been the subject of 4 research reports in the past 90 days.Read more about Alkermes' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth-6.36% Earnings GrowthEarnings for Alkermes are expected to decrease by -6.36% in the coming year, from $2.36 to $2.21 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alkermes is 10.72, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 121.56.Price to Earnings Ratio vs. SectorThe P/E ratio of Alkermes is 10.72, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 126.56.Price to Earnings Growth RatioAlkermes has a PEG Ratio of 0.59. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioAlkermes has a P/B Ratio of 3.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Alkermes' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.00% of the outstanding shares of Alkermes have been sold short.Short Interest Ratio / Days to CoverAlkermes has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.Change versus previous monthShort interest in Alkermes has recently increased by 8.32%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAlkermes does not currently pay a dividend.Dividend GrowthAlkermes does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-1.17 Percentage of Shares Shorted11.00% of the outstanding shares of Alkermes have been sold short.Short Interest Ratio / Days to CoverAlkermes has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.Change versus previous monthShort interest in Alkermes has recently increased by 8.32%, indicating that investor sentiment is decreasing significantly. News and Social Media3.3 / 5News Sentiment0.93 News SentimentAlkermes has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Alkermes this week, compared to 6 articles on an average week.Search Interest2 people have searched for ALKS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows1 people have added Alkermes to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Alkermes insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.89% of the stock of Alkermes is held by insiders.Percentage Held by Institutions95.21% of the stock of Alkermes is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Alkermes' insider trading history. Receive ALKS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alkermes and its competitors with MarketBeat's FREE daily newsletter. Email Address ALKS Stock News HeadlinesArcellx (NASDAQ:ACLX) Stock Quotes, Forecast and News SummaryOctober 8 at 3:23 AM | benzinga.comMizuho maintains Outperform rating on Alkermes stock, optimistic on narcolepsy drugOctober 3, 2024 | uk.investing.comWARNING: “Buffett Indicator” flashing for first time in 50 yearsThe stock market collapsed and didn't recover for an entire decade. And what we're facing today could be even worse. That's why the actions you take in the next 90 days could be crucial for your financial future.October 8, 2024 | Behind the Markets (Ad)Mizuho sustains stock target on Alkermes, cites Takeda studyOctober 3, 2024 | uk.investing.comAlkermes (NASDAQ:ALKS) shareholder returns have been favorable, earning 62% in 5 yearsOctober 2, 2024 | finance.yahoo.comAlkermes plc (NASDAQ:ALKS) Short Interest UpdateSeptember 30, 2024 | americanbankingnews.comAlkermes plc (NASDAQ:ALKS) Receives $36.70 Consensus PT from BrokeragesSeptember 30, 2024 | americanbankingnews.comAlkermes (ALKS) Gets a Hold from Leerink PartnersSeptember 28, 2024 | markets.businessinsider.comSee More Headlines ALKS Stock Analysis - Frequently Asked Questions How have ALKS shares performed this year? Alkermes' stock was trading at $27.74 at the beginning of 2024. Since then, ALKS shares have decreased by 2.3% and is now trading at $27.11. View the best growth stocks for 2024 here. How were Alkermes' earnings last quarter? Alkermes plc (NASDAQ:ALKS) posted its earnings results on Wednesday, July, 24th. The company reported $0.70 EPS for the quarter, hitting the consensus estimate of $0.70. Alkermes's quarterly revenue was down 35.4% on a year-over-year basis. Is Alkermes doing a stock buyback? Alkermes' board initiated a stock buyback plan on Thursday, February 15th 2024, which permits the company to repurchase $400,000,000 in shares, according to EventVestor. This means that the company could purchase up to 8.2% of its stock through open market purchases. Stock buyback plans are often a sign that the company's board of directors believes its shares are undervalued. Does Alkermes have any subsidiaries? The following companies are subsidiaries of Alkermes: Rodin Therapeutics. Who are Alkermes' major shareholders? Alkermes' top institutional investors include Handelsbanken Fonder AB (0.13%), Diversified Trust Co (0.02%), SG Americas Securities LLC (0.01%) and GAMMA Investing LLC. Insiders that own company stock include Richard F Pops, Michael J Landine, Shane Cooke, Blair Curtis Jackson, Christian Todd Nichols, Nancy Wysenski, Cato T Laurencin and Craig C Hopkinson. View institutional ownership trends. How do I buy shares of Alkermes? Shares of ALKS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Alkermes own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alkermes investors own include Gilead Sciences (GILD), Netflix (NFLX), Pfizer (PFE), NVIDIA (NVDA), AbbVie (ABBV), Starbucks (SBUX) and Company Calendar Last Earnings7/24/2024Today10/08/2024Next Earnings (Estimated)10/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:ALKS CUSIPG0176710 CIK1520262 Webwww.alkermes.com Phone(531) 772-8000Fax781-890-0524Employees2,100Year Founded1987Price Target and Rating Average Stock Price Target$36.70 High Stock Price Target$50.00 Low Stock Price Target$25.00 Potential Upside/Downside+35.4%Consensus RatingModerate Buy Rating Score (0-4)2.55 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)$2.53 Trailing P/E Ratio10.72 Forward P/E Ratio11.49 P/E Growth0.59Net Income$355.76 million Net Margins19.15% Pretax Margin20.87% Return on Equity23.20% Return on Assets13.52% Debt Debt-to-Equity Ratio0.22 Current Ratio2.99 Quick Ratio2.61 Sales & Book Value Annual Sales$1.51 billion Price / Sales3.04 Cash Flow$2.19 per share Price / Cash Flow12.38 Book Value$7.21 per share Price / Book3.76Miscellaneous Outstanding Shares169,221,000Free Float160,946,000Market Cap$4.59 billion OptionableOptionable Beta0.46 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:ALKS) was last updated on 10/8/2024 by MarketBeat.com Staff From Our PartnersElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adopti...Porter & Company | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alkermes plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Alkermes With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
